A Single Vaccination of Nonhuman Primates with Highly Attenuated Smallpox Vaccine, LC16m8, Provides Long-term Protection against Monkeypox

Japanese journal of infectious diseases

Ichiro Kurane¹  Yasushi Ami¹  Noriyo Nagata²  Yuriko Suzaki²  Shuetsu Fukushi³  Masashi Mizuguchi³  Hideki Hasegawa⁴  Momoko Ogata⁵  Itoe Iizuka⁵  Shigeru Morikawa⁵  Masayuki Saijo⁶ 

[1] Department of Developmental Medical Sciences, Graduate School of Medicine, The University of Tokyo;Department of Experimental Animals Research, National Institute of Infectious Diseases;Department of Pathology, National Institute of Infectious Diseases;Department of Veterinary Science, National Institute of Infectious Diseases;Laboratory of Special Pathogens, Department of Virology 1, National Institute of Infectious Diseases;National Institute of Infectious Diseases

关键词: LC16m8;    monkeypox;    monkeypox virus;    smallpox vaccine;    vaccinia virus;   

DOI  :  10.7883/yoken.JJID.2016.417

学科分类：传染病学

来源: National Institute of Infectious Diseases

【 摘 要 】

Monkeypox virus (MPXV) causes human monkeypox (human MPX), which is a similar disease to smallpox in humans. A previous study showed that a single vaccination of monkeys with LC16m8, a highly attenuated smallpox vaccine, protected them from MPX from 4-5 weeks post-vaccination. In this study, we evaluated the long-term efficacy of a single vaccination with LC16m8 in a nonhuman primate model of MPXV infection. The monkeys were inoculated with either LC16m8, Lister (parental strain of LC16m8), or a mock-up vaccine, and then challenged with MPXV via a subcutaneous route, at 6 and 12 months after vaccination, which we compared with either Lister or the mock-up vaccination. The LC16m8 monkeys exhibited almost no MPX-associated symptoms, whereas most of the naïve monkeys died. LC16m8 generated the protective memory immune response against MPXV, as suggested by the immediate viremia reduction and the response of the IgG antibody. The results demonstrated that the vaccination of monkeys with a single dose of LC16m8 provided durable protection against MPXV for longer than one year after immunization. The results suggest that the vaccination of humans with LC16m8 could induce long-term protection against MPXV infection.

【 授权许可】

Unknown